SCHEMBL5618200

SCHEMBL5618200

CNc1nccn2c(-c3ccc4[nH]cc(CN(C)C)c4c3)cnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTK P33981 6/20 0.44
▸ FLT3 P36888 4/20 0.42
▸ HTR1A P08908 3/20 0.38
▸ HTR2C P28335 2/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ CYP2D6 P10635 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ HSD17B10 Q99714 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.37
▸ EGFR P00533 1/20 0.36
▸ HTR1D P28221 2/20 0.36
▸ HTR1B P28222 1/20 0.36
▸ GABRP O00591 1/20 0.36
▸ GABRD O14764 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5618193 0.84 PRMT5 (0.39) TTKHTR1AHTR2CCYP3A4CYP2D6
SCHEMBL5618335 0.84 ICMT (0.50) TTKFLT3
SCHEMBL5618954 0.75 FLT3 (0.51) TTKFLT3
SCHEMBL5617891 0.72 FLT3 (0.52) TTKFLT3
SCHEMBL5619194 0.71 FLT3 (0.51) TTKFLT3
SCHEMBL5413864 0.70 KDM4E (0.55) TTKFLT3MEN1KMT2AALDH1A1
SCHEMBL5406217 0.70 FLT3 (0.53) TTKFLT3GABRA1GABRG2GABRB3
SCHEMBL5401140 0.69 FLT3 (0.55) TTKFLT3
SCHEMBL5408543 0.69 FLT3 (0.49) TTKFLT3CYP3A4CYP2D6MEN1
SCHEMBL5401420 0.69 FLT3 (0.56) TTKFLT3MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US claimed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 TTK 69/4885FLT3 216/4885HTR1A 2462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback